Hepatitis C virus (HCV) is a major and growing public health concern. We need to know the expected health burden and treatment cost, and understand uncertainty in those estimates, to inform policymaking and future research. Two models that have been important in informing treatment guidelines and assessments of HCV burden were compared by simulating cohorts of individuals with chronic HCV infection initially aged 20, 35 and 50 years. One model predicts that health losses (measured in quality-adjusted life-years [QALYs]) and treatment costs decrease with increasing initial age of the patients, whilst the other model predicts that below 40 years, costs increase and QALY losses change little with age, and above 40 years, they decline with increasing age. Average per-patient costs differ between the models by up to 38%, depending on the patients' initial age. One model predicts double the total number, and triple the peak annual incidence, of liver transplants compared to the other model.
informed UK guidance, 3 European recommendations 4 and an estimate of UK HCV burden, 5 and Harris et al.'s model 6 has informed an important review 7 and an analysis of treatment prioritization. 8 Here,
we compare the two models in terms of estimated health detriment (quality-adjusted life-year [QALY] loss) and costs to the health service, using a model structure that can represent both models ( Figure 1 ).
| MATERIALS AND METHODS
We implemented Markov models of HCV progression in a cohort of chronically infected individuals, as described by Martin et al 2 ("model A") and Harris et al 6 ("model B"). We consider a closed cohort and do not consider further transmission of infection or re-infection of the cohort after treatment/recovery. The models are illustrated in Figure 1 with corresponding sets of equations in Supporting
Information. Individuals with mild chronic HCV may progress to moderate disease, cirrhosis, decompensated cirrhosis and hepatocellular carcinoma (HCC), whereas model A uses age-invariant annual probabilities of progression estimated by Shepherd et al, 9 and model B has age-dependent probabilities (Table S2) . Individuals with mild disease, moderate disease and cirrhosis receive antiviral treatment of peginterferon-α and ribavirin at fixed rates. Patients in whom sustained virologic response (SVR) does not occur are not eligible to receive further antiviral treatment.
Parameters specifying rates of progression and treatment are in Table S2 , 2, 6, [10] [11] [12] with quality-of-life weights and costs in Table   S1 . 2, 13, 14 Cost parameters, which we inflated to 2015-2016 UK pounds (GBP, £) using the hospital & community health services index, 15, 16 were reported by both Martin et al 2 Health utilities and costs were discounted at 3.5% p.a., as standard for the UK.
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The division between HCV genotypes as described in the two mod- (Table S2) .
| RESULTS

| Effect of initial age on disease burden
The two models differ markedly in how initial age affects their Model A predicts higher discounted costs than model B except at initial ages >40 years but predicts lower discounted QALY losses except at initial ages <29 years. The age dependency of predicted discounted costs and QALY losses is much greater in model A than model B. As disease progression occurs over decades, discounting has an important effect on the net present value of costs and QALY losses, affecting not only the magnitude but also the effect of initial age: without discounting in both models, the costs and QALYs decline monotonically with increasing initial age, and model A predicts lower QALY losses for all but the very youngest initial ages ( Figure 2C ,D).
The models differ markedly in the predicted costs, burden of illness (QALY loss) and the incidence of different stages of disease-both in terms of the timing of progression and the numbers of individuals affected, which will affect the need for particular types of care. We examine these differences below.
| Incidence of progression to disease states
In model A, the incidence of moderate disease is initially highest and declines monotonically over time, whereas in model B for those initially aged 20 and 35 years, the incidence fluctuates over time and is highest around 40 years of age (ie after 20 years in those initially aged 20 years and after 5 years in those initially aged 35 years), and for those initially aged 50 years, incidence is initially highest and then declines almost monotonically ( Figure 3 ).
There is a striking difference between the models regarding the incidence of cirrhosis and HCC ( Figure 3 ). Trends observed in model A are similar for all initial ages, with incidence of cirrhosis peaking at 7-8 cases per 1000 infections after roughly 20 years of infection. Incidence of HCC is low (1-2 cases per 1000 infections per year in all 3 cohorts).
In model B, the incidence of cirrhosis and HCC is much higher and has peaks occurring later (around 80 years of age for cirrhosis and a little older for HCC, regardless of initial age), and rates fluctuate over time due to patterns of age dependence. Both models predict similar incidence of mild SVR (ie successful treatment among those with mild chronic infection), and in both models, the incidence is initially maximal and then declines monotonically 
| Health detriment (QALY losses)
The average discounted QALY loss (due to morbidity and mortality)
per chronic HCV infection estimated by model A is 4.9, 4.1 and 3.1 for those initially aged 20, 35 and 50 years, respectively ( Figure 2B , Mild and moderate disease stages account for 59%-72% of QALY losses in model A and 49%-65% in model B, with the proportion increasing with initial age in both models ( Figure 2B , Table 1 ). Up to half Quality-adjusted life-years losses due to cirrhosis decline with increasing initial age in model A whilst increasing in model B (Table 1 ).
There are also substantial differences in the magnitude of QALY (Table 1) .
| Costs
The cumulative discounted cost per chronic HCV infection declines with increasing initial age in model A (£19 200, £17 100 and £13 800 in those initially aged 20, 35 and 50 years, respectively), whereas in model B, costs increase slightly with initial age (£13 900, £15 100
and £15 300 in those initially aged 20, 35 and 50 years, respectively) ( Table 2 ). Temporal trends in discounted and undiscounted costs in the two models are shown in Figures S5-S8 . Differences between the models are only partially due to the models having different unit costs. When model A's unit costs are used in model B, the predicted discounted costs are higher than using model B's unit costs, being £16 100, £17 300 and £17 300 in those initially aged 20, 35 and 50 years, respectively (Table S3 ). When using model B's unit costs in model A, the average discounted cost in persons initially aged 20, 35 and 50 years is £16 100, £14 400 and £11 700, respectively ( Table S4 ). Note that the trends with initial age were unchanged in each model.
Mild and moderate disease stages account for only one-third of the total discounted cost in model A, whilst accounting for majority of the total cost (>57%) in model B (Table 2) , particularly in the younger ages. If the unit costs from model A are used in model B (Table S3) , then mild and moderate disease stages still account for more than half of the total cost, and if the unit costs from model B are applied to model A (Table S4) , then mild and moderate stages account for ~40% of the total cost, which is still much less than in model B.
Costs due to mild disease decrease with increasing initial age in both models, but the proportion of total costs that they represent increases with initial age in model A whilst declining in model B (Table 2) .
Costs due to moderate disease decrease with increasing initial age in model A and represent a slightly increasing proportion of total costs; in model B, these costs and the proportion of total costs that they represent both increase with increasing initial age ( Table 2 ). These patterns occur regardless of which set of unit costs is used ( Table 2, Tables   S3 and S4 ).
The average discounted costs per patient incurred due to cirrhosis, decompensated cirrhosis, HCC and liver transplantation decrease with increasing initial age in model A, as do the proportions of total discounted costs that they represent (Table 2) T A B L E 1 QALY losses due to morbidity of HCV disease states incurred over the lifetimes of each cohort of 1000 individuals with chronic HCV infection initially aged 20, 35 and 50 years. QALY losses due to mortality are also shown. The percentage of the total QALY loss attributable to morbidity of each disease stage and mortality is also shown. Where applicable, the discount rate used is 3.5% p.a. Table 1 ) and higher average discounted costs (£13 800-£19 200 vs £13 900-£15 300; Table 2 ) than model B (Harris et al   6 ).
The unit cost estimates derived from Harris et al 6 were slightly lower, except for treatment of mild and moderate disease and cirrhosis (Table S1 ), but this was not the major reason for the difference in calculated costs. The two models differ markedly in how the initial age affects their results, with progression rates being age-dependent in with estimates of progression rates that are age-dependent, produces different estimates of costs and QALY losses due to chronic HCV. As
Harris et al's analysis 6 found that rates differ by age, this should be considered in future modelling analyses.
A strength of this study is its systematic comparison of the models, examining the importance of age-dependent progression rates and different estimates of unit costs in contributing to uncertainty. The marked differences between the models of Martin et al 2 and Harris et al 6 are due primarily to differences in progression rates, which determine numbers of individuals in each disease state, and differences in rates of health service utilization associated with each disease state, rather than differences in estimated unit costs to the health service of treating each health state. Further study of progression rates-and factors associated with variation, such as age-and rates of health service utilization associated with different stages of HCV-associated disease is required.
There are other important gaps in knowledge that require further empirical study. As progression from chronic HCV infection through disease states can take decades, the life expectancy of infected individuals could be an important determinant of the cost-effectiveness of treatment. People who inject drugs (PWID) are an important risk group for HCV infection and make up the majority of those infected with HCV in the UK. 19, 20 Treatment as Prevention (TasP) has been advocated for this group, although there are important uncertainties in its likely effectiveness, which depends upon the structure of the network of injecting partners, the coverage of testing and proportion of infected patients who are treated and cured, and the frequency of behaviour change preventing re-infection after successful treatment.
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Further studies of all of these are required, including analysis of potential synergistic effects 22 of combining HCV TasP with needle and syringe programmes (which reduce the infection risk of injecting) and opiate substitution therapy (which assist PWID in stopping injecting).
Use of transmission dynamic models to analyse surveillance data is important in assessing population-level impacts of interventions;
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in the case of PWID, it is important to use models that account for the injecting network structure and dynamics. 21 In some marginalised populations, proactive "find and treat" services may be cost-effective or even cost-saving, as has been found for tuberculosis. (DAAs), which are highly efficacious and well-tolerated but are also expensive, requires further study to determine how to use DAAs in a cost-effective manner. However, if the price paid for DAAs is too high, then this damages overall population health because the money could be used in another way to obtain a greater health gain.
In summary, this research has emphasised the uncertainty in the health burden and economic cost of HCV disease in the UK. The main source of uncertainty is progression rates between disease states and associated rates of health service utilization, particularly with regard to age dependency. In addition, the effects of other risk factors and comorbidities require quantification to improve information for planning and decision-making.
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